NCT01795911View on ClinicalTrials.gov

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

September 30, 2014

Conditions
Hepatitis C
Interventions
BIOLOGICAL

Pegylated Interferon Lambda

DRUG

Ribasphere

DRUG

Daclatasvir

Trial Locations (1)

78215

Alamo Medical Research, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY